[The combined use of inhaled nitric oxide and molecular hydrogen in patients with post-COVID-19 syndrome].
D D Pozdnyakova, I A Baranova, V D Selemir, O S Medvedev, A G Chuchalin · Terapevticheskii arkhiv · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes.
What the Findings Mean
The course of iNO/iН2 and iNO led to regression of the clinical manifestations of PS (dyspnea, cough, fatigue), improved the physical and psychological component of quality of life, and contributed to improvement in microcirculation (increased venule diameter and velocity) compared to the control group (p < 0.05).
What the Researchers Studied
The study used a randomized human clinical trial. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Reported treatment duration: 90 minutes. The course of iNO/iН2 and iNO led to regression of the clinical manifestations of PS (dyspnea, cough, fatigue), improved the physical and psychological component of quality of life, and contributed to improvement in microcirculation (increased venule diameter and velocity) compared to the control group (p < 0.05). The authors concluded that the safety and effectiveness of the iNO/iH2 course has been proven in the form of regression of clinical manifestations of PS, improvement of quality of life, exercise tolerance, microcirculation parameters, and restoration of the oxidative status of the body.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential to influence fatigue-related outcomes and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The reported sample size was 60. The study used a randomized human clinical trial. The reported treatment duration was 90 minutes.
Limitations and Safety
No separate limitations or safety findings were identified in the source text available to H2HUBB.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.